SCHEMBL1051970

SCHEMBL1051970

C#CCN[C@@]1(OS(C)(=O)=O)CCc2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.39
MAOA P21397 5/20 0.39
KDM1A O60341 4/20 0.33
BCHE P06276 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
ACHE P22303 1/20 0.33
ADRA1A P35348 1/20 0.33
HTR6 P50406 1/20 0.33
HDAC9 Q9UKV0 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30
SIGMAR1 Q99720 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16192661 0.78 HDAC9 (0.35) MAOBMAOAHDAC9KMT2AALDH1A1
SCHEMBL1988667 0.77 MAOA (0.35) MAOBMAOAMEN1KMT2A
SCHEMBL4946111 0.74 ACHE (0.41) MAOBMAOABCHEACHE
SCHEMBL2028968 0.72 SIGMAR1 (0.38) KMT2ASIGMAR1
SCHEMBL7947368 0.71 MAOB (0.41) MAOBMAOAKDM1ABCHEADRA2B
SCHEMBL5807645 0.71 KDM1A (0.40) MAOBMAOAKDM1ABCHEADRA2B
SCHEMBL4348712 0.71 MAOB (0.38) MAOBMAOAKDM1ABCHEADRA2B
SCHEMBL7341859 0.71 MAOB (0.38) MAOBMAOAKDM1ABCHEADRA2B
SCHEMBL6472053 0.69 ACHE (0.38) KDM1AACHEMEN1KMT2A
SCHEMBL7743674 0.69 KDM1A (0.41) MAOBKDM1AHDAC9MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118141772-A Ropinirole Luo Jia hydrochloride sulfonic acid rasagiline compound orally disintegrating controlled release tablet and preparation method thereof 四川鲁徽制药有限责任公司 2024-06-07 CN disclosed
CN-116082166-A Preparation method of rasagiline mesylate 上海复旦复华药业有限公司 2023-05-09 CN disclosed
CN-110776429-B Improved preparation method of rasagiline racemic intermediate 齐鲁制药有限公司 2022-12-02 CN disclosed
CN-110776429-A Improved preparation method of rasagiline racemic intermediate 齐鲁制药有限公司 2020-02-11 CN disclosed
CN-102786422-B Method for preparing rasagiline mesylate TOPHARMAN SHANGHAI CO LTD 2015-02-25 CN disclosed
CN-102786422-B Method for preparing rasagiline mesylate TOPHARMAN SHANGHAI CO LTD 2015-02-25 CN disclosed
US-8741962-B2 Process for preparation of Rasagiline and salts thereof USV LIMITED (IN) 2014-06-03 US disclosed
WO-2013168032-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING RASAGILINE MICRO LABS LIMITED (IN) 2013-11-14 WO disclosed
EP-2657221-A1 Preparation of rasagiline and salts thereof Dr. Reddy's Laboratories Ltd. (IN) 2013-10-30 EP disclosed
CN-102786422-A Method for preparing rasagiline mesylate TOPHARMAN SHANGHAI CO LTD 2012-11-21 CN disclosed
EP-2364967-A2 Process for preparation of rasagiline and salts thereof USV Limited (IN) 2011-09-14 EP disclosed
US-20110218360-A1 PREPARATION OF RASAGILINE AND SALTS THEREOF DR. REDDY'S LABORATORIES LTD. (IN) 2011-09-08 US disclosed
EP-2358658-A2 PREPARATION OF RASAGILINE AND SALTS THEREOF Dr. Reddy's Laboratories, Ltd. (IN) 2011-08-24 EP disclosed
US-20110155626-A1 PROCESS FOR PREPARATION OF RASAGILINE AND SALTS THEREOF USV LIMITED (IN) 2011-06-30 US disclosed
US-20110015274-A1 FORM OF AN AMINOINDAN MESYLATE DERIVATIVE MEDICHEM, S.A. (ES) 2011-01-20 US disclosed
WO-2010111264-A2 RASAGILINE FORMULATIONS DR. REDDY'S LABORATORIES LTD. (IN) 2010-09-30 WO disclosed
WO-2010059913-A2 PREPARATION OF RASAGILINE AND SALTS THEREOF DR. REDDY'S LABORATORIES LTD. (IN) 2010-05-27 WO disclosed
US-20100041920-A1 NEW SALT FORMS OF AN AMINOINDAN DERIVATIVE MEDICHEM, S.A. (ES) 2010-02-18 US disclosed
US-20090247537-A1 METHODS FOR PREVENTING OR TREATING BRUXISM USING DOPAMINERGIC AGENTS OVERFIELD WILLIAM DALE 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015274-A1 FORM OF AN AMINOINDAN MESYLATE DERIVATIVE RAB29, RAB6A, QDPR MAOB 491/4885MAOA 404/4885KDM1A 2691/4885
US-20100041920-A1 NEW SALT FORMS OF AN AMINOINDAN DERIVATIVE RAB35, RAB7A, RAB10 MAOB 2254/4885MAOA 1787/4885KDM1A 3588/4885
US-20110155626-A1 PROCESS FOR PREPARATION OF RASAGILINE AND SALTS THEREOF RAB27A, RAB35, RAB7A MAOB 365/4885MAOA 343/4885KDM1A 4069/4885
US-20110218360-A1 PREPARATION OF RASAGILINE AND SALTS THEREOF RAB35, RAB27A, RAB5C MAOB 423/4885MAOA 336/4885KDM1A 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.